Related Experiment Video
Updated: Dec 25, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Knockdown of HSDL2 inhibits lung adenocarcinoma progression via down-regulating AKT2 expression
Yujia Shi1,2, Zhengdao Mao2, Yanhua Huang2
1Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu Province, China.
Abstract:
The aims of the present study are to investigate the role of hydroxysteroid dehydrogenase-like 2 (HSDL2) in the progression of lung adenocarcinoma and illuminate the underlying molecular mechanisms. ShRNA targeting HSDL2 gene (siHSDL2) was utilized to knockdown (KD) HSDL2 expression. In vitro and in vivo experiments were carried out to investigate the effect of siHSDL2 on the progression of lung adenocarcinoma. Microarray hybridization and gene expression analysis were used to investigate effect of siHSDL2 on mRNA expression profile in lung cancer cell line H1299. Our data demonstrated that HSDL2 was up-regulated in lung adenocarcinoma tissue samples (P<0.001). Patients with high HSDL2 expression in cancer tissues had a worse overall survival (P<0.001). HSDL2 KD not only inhibited the proliferation, cell cycle, apoptosis, clone-formation, invasion and migration of lung adenocarcinoma cells in vitro (P<0.05), but also suppressed the growth and metastasis in vivo (P<0.05). HSDL2 KD resulted in up-regulation of 681 genes and down-regulation of 276 genes. HSDL2 KD down-regulated the protein expression and phosphorylation of protein kinase B β (AKT2) (P<0.001 and P<0.001, respectively) and protein expression of baculoviral IAP repeat-containing 3 (BIRC3; P=0.001), and up-regulated the phosphorylation of ERK (P<0.001). Rescue experiments showed that AKT2 overexpression reversed the suppression effect of siHSDL2 on cell proliferation (P<0.001), invasion (P<0.001) and migration (P<0.001) significantly. HSDL2 functions as an oncogene to promote the growth and metastasis of lung adenocarcinoma via promoting the expression of AKT2.
Insights
Hydroxysteroid dehydrogenase-like 2 (HSDL2) promotes lung adenocarcinoma growth and metastasis by upregulating AKT2. Knocking down HSDL2 inhibits cancer progression and improves patient survival, revealing HSDL2 as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Gene Expression Analysis
Background:
- Lung adenocarcinoma is a major cause of cancer mortality.
- The molecular mechanisms driving lung adenocarcinoma progression require further elucidation.
- The role of hydroxysteroid dehydrogenase-like 2 (HSDL2) in lung cancer is not well understood.
Purpose of the Study:
- To investigate the role of HSDL2 in lung adenocarcinoma.
- To identify the molecular mechanisms by which HSDL2 influences lung cancer progression.
- To assess the therapeutic potential of targeting HSDL2.
Main Methods:
- Gene knockdown using small interfering RNA (siHSDL2) to reduce HSDL2 expression.
- In vitro assays (proliferation, cell cycle, apoptosis, clone-formation, invasion, migration) and in vivo studies (growth, metastasis).
- Microarray hybridization and gene expression analysis to profile mRNA changes; Western blotting for protein analysis; rescue experiments with AKT2 overexpression.
Main Results:
- HSDL2 was significantly upregulated in lung adenocarcinoma tissues, correlating with worse patient survival.
- HSDL2 knockdown inhibited lung adenocarcinoma cell proliferation, migration, invasion, and metastasis both in vitro and in vivo.
- HSDL2 knockdown altered gene expression, notably downregulating AKT2 and BIRC3, and upregulating ERK phosphorylation; AKT2 overexpression rescued the inhibitory effects of HSDL2 knockdown.
Conclusions:
- HSDL2 acts as an oncogene promoting lung adenocarcinoma growth and metastasis.
- HSDL2 facilitates lung cancer progression primarily through the AKT2 signaling pathway.
- HSDL2 represents a promising therapeutic target for lung adenocarcinoma treatment.
More Related Videos
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Inhibition of Cdk Activity
Hedgehog Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...